IL-17is demonstrate efficacy in SpA tx Comparable with TNFis & JAKis in terms of achieving ASAS40 response rates IL https://pbs.twimg.com/profile_images/1027501556868870145/2culK0bN_normal.jpg […]
Autolus Therapeutics plc announced the online publication of an abstract submitted to the American College of Rheumatology Convergence 2025, …
Professor James Galloway, honorary consultant rheumatologist and deputy director of the Centre for Rheumatic … rheumatology services. SUGGESTED FORÂ …
Autolus Therapeutics announces the online publication of an abstract for the American College of Rheumatology Convergence 2025. The abstract …
SARD-ILD and serious infection risk: The elephant in the room jsparks@bwh.ha… Tue, 09/16/2025 – 08:00
ILD and Mortality in Systemic Autoimmune Rheumatic Diseases tammytilley@gm… Tue, 09/16/2025 – 08:00 Education/ACR/EULAR Other Rheumatoid Arthritis Cardio/Pulmonary Myositis Scleroderma/Raynauds
Equal Safety of JAK Inhibitors and TNF Inhibitors jjcush@gmail.com Tue, 09/16/2025 – 08:00
Novel research shows that in approximately one third of countries and territories worldwide, population aging was the largest contributor to
… rheumatic diseases, offering an accessible, convenient way to address mental health needs in rheumatology. Written for you by our
… Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025, in Chicago. Autolus will have a poster presentation, which
Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025. Rhea-AI Impact. (Low). Rhea-AIÂ …
The new study in the Annals of the Rheumatic Diseases, published by Elsevier, is poised to inform targeted public health
Curr Allergy Asthma Rep. 2025 Sep 16;25(1):38. doi: 10.1007/s11882-025-01220-x. ABSTRACT PURPOSE OF REVIEW: Lymphoproliferative disorders encompass a variety of hematologic
Rheumatol Int. 2025 Sep 16;45(10):228. doi: 10.1007/s00296-025-05981-6. ABSTRACT Despite increasing recognition of axial spondyloarthritis (axSpA) in Latin America, regional data
J Bone Miner Metab. 2025 Sep 16. doi: 10.1007/s00774-025-01635-6. Online ahead of print. NO ABSTRACT PMID:40956313 | DOI:10.1007/s00774-025-01635-6
Rheumatol Int. 2025 Sep 16;45(10):227. doi: 10.1007/s00296-025-05982-5. ABSTRACT Systemic sclerosis (SSc) and amyloidosis are rare, complex conditions that impair the
J Clin Rheumatol. 2025 Sep 16. doi: 10.1097/RHU.0000000000002282. Online ahead of print. ABSTRACT BACKGROUND/OBJECTIVE: Relapses occur in 14% to 44%
J Clin Rheumatol. 2025 Sep 16. doi: 10.1097/RHU.0000000000002274. Online ahead of print. ABSTRACT BACKGROUND: Cytomegalovirus (CMV) infection is prevalent in
J Clin Rheumatol. 2025 Sep 16. doi: 10.1097/RHU.0000000000002279. Online ahead of print. ABSTRACT BACKGROUND: Pneumocystis jirovecii pneumonia (PJP) is life-threatening
Ther Apher Dial. 2025 Sep 16. doi: 10.1111/1744-9987.70082. Online ahead of print. NO ABSTRACT PMID:40956039 | DOI:10.1111/1744-9987.70082
Epilepsia. 2025 Jul 5. doi: 10.1111/epi.18538. Online ahead of print. ABSTRACT Febrile infection-related epilepsy syndrome (FIRES) is a rare presentation
J Assoc Physicians India. 2025 Sep;73(9S):30-32. doi: 10.59556/japi.73.1135. ABSTRACT Large vessel vasculitis (LVV) is known to affect the aorta and
J Assoc Physicians India. 2025 Sep;73(9):85-90. doi: 10.59556/japi.73.1116. ABSTRACT Sarcopenia and cachexia are two crucial geriatric problems that largely pass
J Assoc Physicians India. 2025 Sep;73(9):e28-e37. doi: 10.59556/japi.73.1124. ABSTRACT OBJECTIVE: The present meta-analysis compares the effectiveness of cyclophosphamide (CYC) as
J Assoc Physicians India. 2025 Sep;73(9):e21-e27. doi: 10.59556/japi.73.1117. ABSTRACT OBJECTIVES: To compare the efficacy and safety of biosimilar adalimumab injection
Elife. 2025 Sep 16;13:RP101137. doi: 10.7554/eLife.101137. ABSTRACT The discovery of genetic alterations in patient samples over the last decades has
J Assoc Physicians India. 2025 Aug;73(8):67-76. doi: 10.59556/japi.73.1084. ABSTRACT OBJECTIVE: The current management of osteoporosis has several unmet needs. Consequently,
